COVID-19 Fact or Fiction? Remdesivir
Apr 21, 2020, 11:55 EDT
Find the answer here.
ANSWER: FACT – A compassionate use study in 53 patients with severe COVID-19 found that in 68% of treated patients with remdesivir experienced clinical improvement.
- Compassionate Use of Remdesivir for Patients with Severe COVID-19 was published in the New England Journal of Medicine on April 10, 2020.
- Participants had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support.
- Intervention – 10-day course of remdesivir (200 mg IV day 1, then 100 mg IV daily for 9 more days).
- At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation.
- During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated.
- A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation.
This small non-blinded compassionate study demonstrated that remdesivir may help to improve outcomes. A measurement of efficacy would require an ongoing placebo-controlled trial.
The recommendations on COVID-19 are constantly changing. Clinicians are strongly advised to seek current evidence and expert recommendations before making clinical treatment decisions.